Business Wire

KVANTO-PAYMENT-SOLUTIONS

6.2.2020 09:02:10 CET | Business Wire | Press release

Share
Kvanto Announces NEW Edge Partnership World Wide EU

For Pure Health inc. (FPH) has signed a partnership agreement with Kvanto Payment Services A/S (hereafter Kvanto). FPH provides sales all over the globe. All numbers and assumptions are based on previous first-hand experience with similar setups and products. And has made it before and they have entered with Kvanto and using the Payment Gateway, this has a large opportunity.

“FPH was looking for a partner to handle payments solution. One of the most important things for FPH is that customers experience has a smooth and secure checkout when buying our products from our website.

Kvanto Payment services not only provided us with this solution but also helped us set up the system, quickly and seamlessly. Furthermore, FPH has trusted Kvanto Payment Services with helping FPH with administration, technical, and development.

This special cooperation we have not been able to find elsewhere. From the start of this cooperation, we have made this as a focus development case, and we are now moving it to a slot of large opportunities of 250M € turnover a year and our aim is larger, and Kvanto stands the challenge and we have been satisfying so fare.

Allan Djurhuus
CEO, FPH Inc
.”

Benefits compared to other solution partners

Kvanto has an MPI security Solution, it works outside Europe, and that’s where we have most of the clients in FPH. Kvanto makes sure the merchant’s customer and the cardholder are the same person by sending a code to the customer's cell phone, which the customer must fill into the payment window before the payment is approved.

FPH has made this happen, through our marketing corporation with Konnektive CRM in US/PR and we have worked with Konnektive CRM for years now, and it has been a huge success, and we are so delighted to manage to get both Kvanto and Konnektive CRM together, and we have now one solution, and that saves us a large amount of time and money, we can´s understand why people not are managing this as it has to be, and as Konnektive is saying.

“Time is money.
With hundreds of integrations through Konnektive, you’ll never be scrambling to find your data by going to multiple systems. We put everything you need at your fingertips; all in one place!

Konnektive CRM was designed to Automate and Synchronize Your Entire Business with the easiest, most intuitive user interface.
Brian Bolerjack,
Konnektive CRM”

Kvanto cooperation with both the system provider and customer

Kvanto has made an option and an opportunity by creating this cooperation, to manage a whole platform, by offering the Kvanto ESB Payment Gateway, and support the individual customer and the whole group of Konnektive CRM platform solution, as a trusted partner. Kvanto has proved to be highlighted as a service provider that can handle payment transactions across the payment ECO-system, and even if you are making the payment happen in Europe or elsewhere, we can carry the solution to a new level of security by Kvanto MPI solution.

Value proposition

By managing this, and through the Kvanto Gateway Solution, it will be possible to draw more potential clients into our merchants, and our expectation of this cooperation is more than 12 Mill $ in turnover a year, on this case alone.

And the options for new clients is much higher, and we can multiply this 3-4 times.

This is an optimizing way of creating new clients, and we have today two new clients, that bring more merchants in through this cooperation, and we expect to reach some 15-22 clients with the support we have from Konnektive CRM staff and PR from FPH.

About Kvanto Payment Solutions

Kvanto is a Payment Solution Provider company that provides simple, flexible, and cost-efficient payment solutions on the global market. Through experience and knowledge does Kvanto challenge current structures and procedures in the established market.

Kvanto strives to be a one-stop-shop for payments with cross border solutions for merchants and the leading EMEA/APAC multi-connectivity payment solutions provider measured in processing volume while being profitable.

For further investor enquires
Listing Partners LLC
support@listingpartners.lu

All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Kvanto Payment Systems A/S is under no obligation to (and expressly disclaim any such obligation to) update or alters our forward-looking statements, whether as a result of new information, future events, or otherwise.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye